Research on Nutritional Risk Indexes and Inflammatory Indicators in Postoperative Complications and Prognosis of Epithelial Ovarian Cancer Patients

Qinglei Gao1,108 enrolled

Overview

The goal of this observational study is to explore the influence and predictive significance of nutritional risk indicators and inflammatory indicators on postoperative complications and prognosis of patients with epithelial ovarian cancer (EOC). The main question it aims to answer is: Can preoperative nutritional risk and inflammatory indexes predict postoperative complications? Do preoperative nutritional risk and inflammatory indexes better predict the prognosis of patients with epithelial ovarian cancer? Which index is the best predictor of postoperative complications or prognosis for patients?

Study Type

OBSERVATIONAL

Enrollment

1,108

Conditions

Epithelial Ovarian Cancer

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: 1. histologically confirmed primary epithelial ovarian, peritoneal, and fallopian tube cancers. 2. patients received comprehensive staged surgery or debulking surgery. 3. available data of laboratory examination within 7 days before the surgery. Exclusion Criteria: 1. borderline ovarian tumor. 2. receipt of neoadjuvant chemotherapy. 3. presence of other conditions influencing laboratory data, like hepatitis, kidney disease, autoimmune diseases, infectious diseases, blood disease, etc. 4. concurrent cancer in other organs. 5. absence of surgery or biopsy only. 6. multiple staged surgeries.

Outcomes

Primary Outcomes

Postoperative Complications

Progression-free survival

Interval between first diagnosis and first recurrence, death, or last follow-up

Time frame: From the date the patient diagnosed with primary ovarian, fallopian tube, or peritoneal cancer to the date of disease progression or death or last follow-up, whichever occurred first, assessed up to 100 months.

Overall survival

Interval between first diagnosis and death, or last follow-up

Time frame: From the date the patient diagnosed with primary ovarian, fallopian tube, or peritoneal cancer to the date of death or last follow-up, whichever occurred first, assessed up to 100 months.